ADMA Biologics, Inc. (NASDAQ:ADMA) CFO Brad L. Tade Sells 15,000 Shares of Stock

ADMA Biologics, Inc. (NASDAQ:ADMA) CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares in the company, valued at $4,218,007.95. This represents a 7.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

ADMA Biologics Price Performance

NASDAQ:ADMA opened at $21.18 on Friday. The company has a market capitalization of $5.01 billion, a price-to-earnings ratio of 75.64 and a beta of 0.64. The company has a 50-day moving average of $18.86 and a 200-day moving average of $14.83. ADMA Biologics, Inc. has a 52 week low of $3.60 and a 52 week high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.02. The firm had revenue of $119.84 million during the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same period in the prior year, the company posted $0.01 earnings per share. As a group, equities research analysts anticipate that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ADMA has been the subject of several research reports. Raymond James lifted their price target on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright boosted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th.

Institutional Trading of ADMA Biologics

Several hedge funds have recently modified their holdings of ADMA. Quest Partners LLC bought a new stake in ADMA Biologics during the 2nd quarter worth approximately $29,000. Hollencrest Capital Management acquired a new position in ADMA Biologics in the third quarter worth $30,000. EntryPoint Capital LLC bought a new stake in shares of ADMA Biologics during the first quarter worth $31,000. Larson Financial Group LLC bought a new stake in shares of ADMA Biologics during the third quarter worth $31,000. Finally, National Bank of Canada FI bought a new position in shares of ADMA Biologics in the third quarter valued at about $35,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.